ClinicalTrials.gg
Status unknownNCT04456881Updated Apr 18, 2023

Arthroscopic Clinical Study of Double Bundle Anatomical Reconstruction of Medial Patellofemoral Ligament

An interventional study of Patients with patellar dislocation undergo patellar femoral medial reconstruction in Recurrent Patellar Dislocation, sponsored by Peking University Third Hospital. Status unknown at 1 site in China. Open to participants aged 17 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-04-18.

Sponsored by Peking University Third Hospital · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jan 2023), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2020, registered Jun 2020).
Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
17 Years to 60 Years
Sex
All
01

Study summary

Objective: To study the clinical effect of double-beam anatomical reconstruction of medial patellofemoral ligament under arthroscopy.

Methods: Double-beam anatomical reconstruction of medial patellofemoral ligament was performed under arthroscopy in patients admitted to our hospital for treatment of recurrent patellar dislocation. Carry out preoperative and postoperative evaluations, and conduct preoperative and postoperative comparative studies to clarify the clinical effect of the procedure.

Expected results: Arthroscopic double-beam anatomical reconstruction of the medial patellofemoral ligament can effectively restore the stability of the patella and the motor function of the knee joint.

Expected conclusion: Arthroscopic double-beam anatomical reconstruction of the medial patellofemoral ligament is an effective minimally invasive technique.

Keywords: knee joint; medial patellofemoral ligament; double-beam anatomical reconstruction; arthroscopy

02

Conditions studied

  • Recurrent Patellar Dislocation

Browse trials for

Keywords

  • arthroscopy
  • medial patellofemoral ligament
03

In context

Patellar Dislocation

41 studies on the registry are indexed under Patellar Dislocation; 9 are open to participants now.

This study's planned enrollment of 30 is below the median of 50 across 22 interventional studies indexed under Patellar Dislocation.

Browse Patellar Dislocation studies →

Lead sponsor

Peking University Third Hospital is the lead sponsor of 752 studies on the registry; 273 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
17 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 17\<age\<60 years
  • Recurrent patellar dislocation or instability

Exclusion criteria

Exclusion Criteria:

  • Bone spurs or bone protrusions on the D-type of the femoral pulley or proximal of the pulley.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    anatomical reconstruction group of Patellofemoral ligament

    Other: Patients with patellar dislocation undergo patellar femoral medial reconstruction

Interventions

  • OtherPatients with patellar dislocation undergo patellar femoral medial reconstruction

    Arthroscopic double-beam anatomical reconstruction of medial patellofemoral ligament

06

What researchers measure

Primary outcomes

  1. Lysholm score

    The Lysholm score consists of eight items including limping, locking, pain, stair climbing, use of supports, instability, swelling, and squatting. The higher values represent a better outcome.

    Time frame: 1 year after operation

  2. International Knee Documentation Committee (IKDC) 2000

    International Knee Documentation Committee (IKDC) 2000. The higher values represent a better outcome.

    Time frame: 1 year after operation

  3. Tegner activity level score

    The highest level of activity that you participated in before your injury and the highest level you are able to participate in currently. The higher values represent a better outcome.

    Time frame: 1 year after operation

07

Study locations

1 of 1 sites recruiting
  • Institute of Sports Medicine, Peking University Third Hospital, Beijing Key Laboratory of Sports Injuries, Beijing, China
    Beijing, Beijing 100191, China
    Recruiting
    • Ping Liu · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2020 (actual). Primary completion is estimated for Feb 2024, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 27, 2020
First posted
Jul 7, 2020
StartActual
Jan 1, 2020
Primary completionEst.
Feb 1, 2024
CompletionEst.
May 1, 2024
Last update
Apr 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04456881
Responsible party
Sponsor
First posted
Jul 7, 2020
Start date
Jan 1, 2020
Primary completion
Feb 1, 2024 (estimated)
Completion
May 1, 2024 (estimated)
Last update
Apr 18, 2023

Study contacts

Ping Liu
Contact
bjusmlp@126.com
13683670396

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion